• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重塑疫苗:疾病预防中的肽革命。

Vaccines reimagined: The peptide revolution in disease prevention.

作者信息

Chavda Vivek P

机构信息

Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Ahmedabad, Gujarat, India.

出版信息

Prog Mol Biol Transl Sci. 2025;212:329-354. doi: 10.1016/bs.pmbts.2024.11.002. Epub 2025 Jan 30.

DOI:10.1016/bs.pmbts.2024.11.002
PMID:40122650
Abstract

Peptide-based vaccines have emerged as a promising avenue in the realm of immunization strategies. This chapter provides an overview of the key aspects and advancements in peptide-based vaccine development. Peptides, as fragments of larger proteins, hold the potential to induce targeted immune responses while minimizing off-target effects. We discuss the principles of peptide selection, epitope identification, and delivery platforms, underscoring the importance of rational design to optimize immunogenicity. The integration of computational tools and advanced analytical methods has enabled the refinement of peptide vaccine candidates. Studies on infectious diseases, cancers, and new pathogens showcase the versatility and efficacy of peptide vaccines. As the field progresses, collaborative efforts between researchers, industry, and healthcare systems are essential to bridge the gap from laboratory research to clinical application. The future holds promise for peptide-based vaccines to contribute significantly to disease prevention and therapeutic intervention.

摘要

基于肽的疫苗已成为免疫策略领域中一条充满希望的途径。本章概述了基于肽的疫苗开发的关键方面和进展。肽作为较大蛋白质的片段,有潜力诱导靶向免疫反应,同时将脱靶效应降至最低。我们讨论了肽的选择、表位鉴定和递送平台的原则,强调了合理设计以优化免疫原性的重要性。计算工具和先进分析方法的整合使得候选肽疫苗得以优化。对传染病、癌症和新病原体的研究展示了肽疫苗的多功能性和有效性。随着该领域的发展,研究人员、产业界和医疗保健系统之间的合作努力对于弥合从实验室研究到临床应用的差距至关重要。基于肽的疫苗未来有望为疾病预防和治疗干预做出重大贡献。

相似文献

1
Vaccines reimagined: The peptide revolution in disease prevention.重塑疫苗:疾病预防中的肽革命。
Prog Mol Biol Transl Sci. 2025;212:329-354. doi: 10.1016/bs.pmbts.2024.11.002. Epub 2025 Jan 30.
2
Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines.肿瘤衍生抗原肽作为潜在的癌症疫苗。
Int J Mol Sci. 2024 Apr 30;25(9):4934. doi: 10.3390/ijms25094934.
3
Peptide-Based Vaccines for Tuberculosis.基于肽的结核病疫苗。
Front Immunol. 2022 Jan 31;13:830497. doi: 10.3389/fimmu.2022.830497. eCollection 2022.
4
Recent Advances in the Development of Protein- and Peptide-Based Subunit Vaccines against Tuberculosis.基于蛋白质和肽的抗结核亚单位疫苗研发的最新进展
Cells. 2020 Dec 15;9(12):2673. doi: 10.3390/cells9122673.
5
Rational Design of Antigen Incorporation Into Subunit Vaccine Biomaterials Can Enhance Antigen-Specific Immune Responses.抗原在亚单位疫苗生物材料中的合理设计可以增强抗原特异性免疫反应。
Front Immunol. 2020 Jul 21;11:1547. doi: 10.3389/fimmu.2020.01547. eCollection 2020.
6
Next-generation Dengue Vaccines: Leveraging Peptide-Based Immunogens and Advanced Nanoparticles as Delivery Platforms.下一代登革热疫苗:利用基于肽的免疫原和先进的纳米颗粒作为递送平台。
J Pharm Sci. 2024 Aug;113(8):2044-2054. doi: 10.1016/j.xphs.2024.05.010. Epub 2024 May 16.
7
Epitope discovery and their use in peptide based vaccines.表位发现及其在基于肽的疫苗中的应用。
Curr Pharm Des. 2010;16(28):3149-57. doi: 10.2174/138161210793292447.
8
Peptide Immunotherapy in Vaccine Development: From Epitope to Adjuvant.肽疫苗免疫治疗:从表位到佐剂。
Adv Protein Chem Struct Biol. 2015;99:1-14. doi: 10.1016/bs.apcsb.2015.03.001. Epub 2015 Apr 8.
9
The bright side of chemistry: Exploring synthetic peptide-based anticancer vaccines.化学的光明面:探索基于合成肽的抗癌疫苗。
J Pept Sci. 2024 Aug;30(8):e3596. doi: 10.1002/psc.3596. Epub 2024 Apr 3.
10
Immunogenicity of multi-epitope-based vaccine candidates administered with the adjuvant Gp96 against rabies.与佐剂Gp96联合使用的多表位狂犬病候选疫苗的免疫原性。
Virol Sin. 2016 Apr;31(2):168-75. doi: 10.1007/s12250-016-3734-4. Epub 2016 Apr 6.